WATCH 👀: Johanna Enke, MD, of @UCLAHealth discusses safety findings from a phase 2 study of lutetium Lu 177 vipivotide tetraxetan rechallenge in mCRPC at #ESMO26

See here ➡️: https://www.onclive.com/view/dr-enke-on-interim-safety-data-for-lutetium-lu-177-vipivotide-tetraxetan-retreatment-in-mcrpc

#pcsm #oncology